Vaccines - Tunisia

Tunisia

The Vaccines market in Tunisia is forecasted to witness a substantial growth in revenue, with an estimated value of US$27.26m in 2024.
This projection indicates a positive trend in the market's financial performance.
Furthermore, it is expected that the market will experience a steady annual growth rate (CAGR 2024-2029) of -2.21%, resulting in a market volume of US$24.38m by 2029.
These figures highlight the potential for significant expansion within the Vaccines market.
When compared globally, it is noteworthy that United States is expected to generate the highest revenue within the Vaccines market, reaching an impressive US$29,120.00m in 2024.
This demonstrates United States' dominance in the market and its significance as a key player in the industry.
Tunisia has seen a significant increase in the demand for vaccines, driven by the government's efforts to improve public health and prevent the spread of infectious diseases.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Tunisia has been increasing steadily in recent years.

Customer preferences: Customers in Tunisia have shown a growing interest in vaccines due to increased awareness and education about the importance of vaccination. Parents are increasingly vaccinating their children against preventable diseases, and there is also a growing demand for vaccines among adults.

Trends in the market: The Tunisian government has been investing heavily in the healthcare sector, including the vaccination program. The government has been working to increase the availability and accessibility of vaccines, particularly in rural areas. In addition, there has been a growing trend towards the development of new vaccines, as well as the expansion of existing vaccine markets.

Local special circumstances: Tunisia has a high prevalence of infectious diseases, including hepatitis B, measles, and tuberculosis. This has contributed to the high demand for vaccines in the country. In addition, the country has a large population of young people, which has also contributed to the growth of the vaccine market.

Underlying macroeconomic factors: The Tunisian economy has been growing steadily in recent years, which has contributed to the growth of the healthcare sector. In addition, the government has been working to attract foreign investment, which has helped to stimulate the vaccine market. The country's strategic location in North Africa has also made it an attractive destination for pharmaceutical companies looking to expand their operations in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.